JP2023536589A5 - - Google Patents
Info
- Publication number
- JP2023536589A5 JP2023536589A5 JP2023507253A JP2023507253A JP2023536589A5 JP 2023536589 A5 JP2023536589 A5 JP 2023536589A5 JP 2023507253 A JP2023507253 A JP 2023507253A JP 2023507253 A JP2023507253 A JP 2023507253A JP 2023536589 A5 JP2023536589 A5 JP 2023536589A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- alkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059959P | 2020-07-31 | 2020-07-31 | |
| US63/059,959 | 2020-07-31 | ||
| PCT/US2021/044004 WO2022026892A1 (en) | 2020-07-31 | 2021-07-30 | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536589A JP2023536589A (ja) | 2023-08-28 |
| JP2023536589A5 true JP2023536589A5 (https=) | 2024-08-07 |
Family
ID=78000758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507253A Pending JP2023536589A (ja) | 2020-07-31 | 2021-07-30 | Ｍｔａｐ欠損及び／またはｍｔａ蓄積癌の治療に有用なピペリジン－１－イル－ｎ－ピリジン－３－イル－２－オキソアセトアミド誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11492350B2 (https=) |
| EP (1) | EP4188920A1 (https=) |
| JP (1) | JP2023536589A (https=) |
| KR (1) | KR20230094196A (https=) |
| CN (1) | CN116568677A (https=) |
| AR (1) | AR123127A1 (https=) |
| AU (1) | AU2021319201A1 (https=) |
| CA (1) | CA3176912A1 (https=) |
| IL (1) | IL300147A (https=) |
| MX (1) | MX2023001379A (https=) |
| WO (1) | WO2022026892A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| KR20240148320A (ko) * | 2021-12-17 | 2024-10-11 | 탱고 테라퓨틱스, 인크. | N-(6-아미노-5-메틸피리딘-3-일)-2-(벤조[d]티아졸-5-일)-5-메틸피페리딘-1-일)-2-옥소아세트아마이드의결정질 형태, 약제학적 조성물 및 이의 사용 방법 |
| EP4469438A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP4469447A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| JP2025504916A (ja) * | 2022-01-26 | 2025-02-19 | タンゴ セラピューティクス， インコーポレイテッド | 化合物及び使用方法 |
| WO2023146991A1 (en) * | 2022-01-26 | 2023-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2024022433A1 (zh) * | 2022-07-28 | 2024-02-01 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| AU2023327684A1 (en) | 2022-08-15 | 2025-03-20 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| CN119744263A (zh) * | 2022-08-19 | 2025-04-01 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| CN119731162A (zh) * | 2022-08-19 | 2025-03-28 | 北京望实智慧科技有限公司 | Prmt5抑制剂 |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| AU2023366908A1 (en) * | 2022-10-25 | 2025-05-08 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2024104244A1 (zh) * | 2022-11-15 | 2024-05-23 | 四川科伦博泰生物医药股份有限公司 | 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024131918A1 (zh) * | 2022-12-22 | 2024-06-27 | 成都苑东生物制药股份有限公司 | 一种取代草酰胺类衍生物、其制备方法及用途 |
| CN120476118A (zh) * | 2023-01-17 | 2025-08-12 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN118103373A (zh) | 2023-01-18 | 2024-05-28 | 上海德琪医药科技有限公司 | Prmt5抑制化合物和其用途 |
| CN120457129A (zh) * | 2023-01-31 | 2025-08-08 | 四川科伦博泰生物医药股份有限公司 | 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| WO2025016323A1 (zh) | 2023-07-14 | 2025-01-23 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| TW202521525A (zh) | 2023-08-09 | 2025-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜芳基化合物、其製備方法及其在醫藥上的應用 |
| WO2025039979A1 (zh) | 2023-08-18 | 2025-02-27 | 江苏亚虹医药科技股份有限公司 | 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途 |
| WO2025059579A1 (en) | 2023-09-15 | 2025-03-20 | Ideaya Biosciences, Inc. | Methods of treating mat2a related diseases |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN120309628A (zh) * | 2024-01-13 | 2025-07-15 | 艾立康药业股份有限公司 | 一种prmt5抑制剂及其组合物和药物用途 |
| WO2025166186A1 (en) * | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025166308A1 (en) | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025217297A1 (en) | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
| WO2025218671A1 (en) * | 2024-04-16 | 2025-10-23 | Shanghai Apeiron Therapeutics Company Limited | Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use |
| CN121021512A (zh) * | 2024-05-28 | 2025-11-28 | 艾立康药业股份有限公司 | 一类prmt5抑制剂及其组合物和用途 |
| WO2025260063A2 (en) | 2024-06-13 | 2025-12-18 | Tango Therapeutics, Inc. | Methods of preparing a prmt5 inhibitor |
| WO2026067820A1 (zh) * | 2024-09-30 | 2026-04-02 | 江苏恒瑞医药股份有限公司 | 螺杂环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69622148T2 (de) | 1995-09-28 | 2002-10-31 | Suntory Limited, Osaka | Chinazozin derivate und deren verwendung |
| WO2004096774A1 (en) | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
| WO2012058645A1 (en) * | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| DK2935222T3 (en) | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US20170210751A1 (en) | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3191592A1 (en) | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| US20170280720A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016089883A1 (en) | 2014-12-01 | 2016-06-09 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| JP6832430B2 (ja) * | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US20190083482A1 (en) | 2017-09-18 | 2019-03-21 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2019084470A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| JP2021505583A (ja) | 2017-12-05 | 2021-02-18 | エンジェクス ファーマシューティカル インコーポレイテッド | Ｐｍｒｔ５阻害剤としての複素環式化合物 |
| US11059850B2 (en) | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
| US20190175526A1 (en) | 2017-12-13 | 2019-06-13 | Macau University Of Science And Technology | Methods for treating cancer |
| US10278955B1 (en) | 2017-12-13 | 2019-05-07 | Macau University Of Science And Technology | Methods of treating cancer |
| SMT202200396T1 (it) | 2017-12-13 | 2022-11-18 | Lupin Ltd | Composti eterociclici biciclici sostituiti come inibitori di prmt5 |
| CA3091041A1 (en) | 2018-02-22 | 2019-08-29 | Ichan School Of Medicine At Mount Sinai | Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use |
| KR102522856B1 (ko) | 2018-03-09 | 2023-04-19 | 파마블럭 사이언시스 (난징), 인코포레이티드 | 단백질 아르기닌 메틸전이효소 5(prmt 5)의 억제제, 이의 약학적 제품 및 이의 방법 |
| WO2019180628A1 (en) | 2018-03-22 | 2019-09-26 | Aurigene Discovery Technologies Limited | Imidazolidin-2-one compounds as prmt5 modulators |
| BR112020019111A2 (pt) | 2018-03-22 | 2021-01-12 | Aurigene Discovery Technologies Limited | Derivados de imidazolidin-2-ona substituída como inibidores de prmt5 |
| WO2019219805A1 (en) | 2018-05-16 | 2019-11-21 | Ctxone Pty Ltd | Combination therapy |
| US20210267973A1 (en) | 2018-05-31 | 2021-09-02 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CA3118175A1 (en) | 2018-11-08 | 2020-05-14 | Glaxosmithkline Intellectual Property Development Limited | Combination of prmt5 inhibitors and bcl-2 inhibitors |
| LT3902803T (lt) * | 2018-12-27 | 2023-04-25 | Les Laboratoires Servier | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui |
| EP3924360A1 (en) | 2019-02-13 | 2021-12-22 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| CN113330009B (zh) | 2019-03-12 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| WO2020198601A1 (en) | 2019-03-27 | 2020-10-01 | University Of Virginia Patent Foundation | Combinatorial drug treatment of cancer |
| WO2020205660A1 (en) | 2019-03-29 | 2020-10-08 | University Of Florida Research Foundation, Incorporated | Prmt5 inhibitor compounds |
| MA55556A (fr) | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
| WO2020206289A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| WO2020206308A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| JP2022526604A (ja) | 2019-04-05 | 2022-05-25 | プレリュード・セラピューティクス・インコーポレイテッド | タンパク質アルギニンメチルトランスフェラーゼ５の選択的阻害剤 |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| WO2021004547A1 (en) | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20230062119A1 (en) | 2019-12-17 | 2023-03-02 | Merck Sharp & Dohme Llc | Use of biomarkers in identifying patients that will be responsive to treatment with a prmt5 inhibitor |
| CN114929234A (zh) | 2020-01-07 | 2022-08-19 | 辉瑞公司 | 用于治疗银屑病及其他自体免疫性病况的方法中的prmt5抑制剂 |
| WO2021163344A1 (en) | 2020-02-12 | 2021-08-19 | Amgen Inc. | Novel prmt5 inhibitors |
| WO2022026892A1 (en) * | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| WO2022115377A1 (en) | 2020-11-24 | 2022-06-02 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| UY39565A (es) | 2020-12-16 | 2022-06-30 | Amgen Inc | Inhibidores de prmt5 novedosos |
| EP4347569A4 (en) | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| WO2023098439A1 (zh) | 2021-11-30 | 2023-06-08 | 上海和誉生物医药科技有限公司 | 一种吡唑衍生物，其制备方法和在药学上的应用 |
| CN116462677A (zh) | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
| CN116462676A (zh) | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
-
2021
- 2021-07-30 WO PCT/US2021/044004 patent/WO2022026892A1/en not_active Ceased
- 2021-07-30 IL IL300147A patent/IL300147A/en unknown
- 2021-07-30 CA CA3176912A patent/CA3176912A1/en active Pending
- 2021-07-30 KR KR1020237006890A patent/KR20230094196A/ko active Pending
- 2021-07-30 JP JP2023507253A patent/JP2023536589A/ja active Pending
- 2021-07-30 EP EP21783067.8A patent/EP4188920A1/en active Pending
- 2021-07-30 MX MX2023001379A patent/MX2023001379A/es unknown
- 2021-07-30 CN CN202180067678.XA patent/CN116568677A/zh active Pending
- 2021-07-30 AU AU2021319201A patent/AU2021319201A1/en active Pending
- 2021-08-02 AR ARP210102152A patent/AR123127A1/es unknown
- 2021-11-12 US US17/525,692 patent/US11492350B2/en active Active
-
2022
- 2022-04-29 US US17/732,846 patent/US11999727B2/en active Active
-
2024
- 2024-02-01 US US18/430,456 patent/US12264154B2/en active Active
- 2024-02-01 US US18/430,429 patent/US12304907B2/en active Active
-
2025
- 2025-02-20 US US19/058,661 patent/US20260078117A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536589A5 (https=) | ||
| US10995078B2 (en) | Compounds and compositions for inhibition of FASN | |
| JP5518072B2 (ja) | Ｐｉｍキナーゼ阻害剤としてのトリアゾロピリジン化合物 | |
| TWI429434B (zh) | 作為受體酪胺酸激酶抑制劑之咪唑并〔１，２-ａ〕吡啶化合物 | |
| JP5808793B2 (ja) | キナーゼ調節のための化合物および方法、ならびにそれらの適応症 | |
| JP5827627B2 (ja) | ＴＧＦ−β受容体キナーゼ阻害剤としてのヘテロアリールアミノキノリン | |
| AU2009278442B2 (en) | Imidazopyridin-2-one Derivatives | |
| KR101609412B1 (ko) | 아자 2 고리형 화합물 또는 그 염 | |
| CN113164459B (zh) | 单酰基甘油脂肪酶调节剂 | |
| CA3075727A1 (en) | Pyridazinones and methods of use thereof | |
| RU2014119244A (ru) | Гетероциклические соединения и способы их использования | |
| JP2017510576A5 (https=) | ||
| JP6900491B2 (ja) | ピラゾロピリミジン化合物及びその使用方法 | |
| JP2002522452A5 (https=) | ||
| TWI822754B (zh) | 作為crhr2拮抗劑之稠合環狀脲衍生物 | |
| JP2014528482A5 (https=) | ||
| JP7002335B2 (ja) | Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン | |
| TW202339737A (zh) | 化合物及使用方法 | |
| US11649241B2 (en) | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | |
| TW201919708A (zh) | 與ido之表現有關之疾病之預防及/或治療劑 | |
| CN114008050A (zh) | Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途 | |
| AU2022421952A1 (en) | Arylsulphonamide compounds | |
| JP2011178779A (ja) | イミダゾピリジン−２−オン誘導体 | |
| CN107428750A (zh) | 三唑并吡啶化合物及其使用方法 | |
| RU2020134947A (ru) | Производные конденсированной циклической мочевины в антагонист crhr2 |